tiprankstipranks
Trending News
More News >

Akoya Biosciences Completes Merger and Nasdaq Delisting

Story Highlights
Akoya Biosciences Completes Merger and Nasdaq Delisting

Don’t Miss TipRanks’ Half-Year Sale

Akoya Biosciences ( (AKYA) ) has issued an update.

On July 8, 2025, Akoya Biosciences, a company involved in a merger, repaid all outstanding obligations under its Credit Agreement and terminated its Employee Stock Purchase Plan and Equity Distribution Agreement. The merger resulted in the conversion of Akoya’s common stock into Quanterix shares and cash, adjustments to stock options and restricted stock units, and significant changes in Akoya’s board and executive officers. Akoya also requested the suspension of its stock trading on Nasdaq and plans to terminate its stock registration and reporting obligations.

The most recent analyst rating on (AKYA) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Akoya Biosciences stock, see the AKYA Stock Forecast page.

Spark’s Take on AKYA Stock

According to Spark, TipRanks’ AI Analyst, AKYA is a Neutral.

Akoya Biosciences faces substantial financial hurdles with persistent losses and high leverage, significantly impacting the overall score. While short-term technical indicators show some positive momentum, long-term trends remain bearish. The amended merger agreement with Quanterix is a potential positive catalyst, but the negative P/E ratio limits valuation attractiveness.

To see Spark’s full report on AKYA stock, click here.

More about Akoya Biosciences

Average Trading Volume: 582,355

Technical Sentiment Signal: Sell

Current Market Cap: $64.44M

See more insights into AKYA stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1